Skip to main content

Table 3 Random-effects pooled results: pregabalin vs. placebo.

From: Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Outcome Treatment effect (θ) 95% CI for θ U-test
(p-value)
τ 2 NNT/NNH
(95% CI)
Efficacy      
Reduction in 24-hour pain intensity -0.901 (-1.234; -0.568) <0.001 0.147  
Response 0.840 (0. 524; 1.155) <0.001 0.154 5(4;8)
PGI -1.291 (-1.722; -0.860) <0.001 0.019  
Tolerability      
Premature study discontinuation due to:      
- Lack of efficacy 0.713 (-1.205; -0.221) (0.005) 0  
- Adverse events 0.926 (0.463; 1.389) <0.001 0 19 (10; 48)
- Other -0.209 (-0.721; 0.302) (0.330) 0  
Diarrhoea -0.660 (-1.734; 0.414) 0.139 0.139  
Dizziness 1.900 (1.314; 2.487) 0.028 0.028  
Headache -0.216 (-0.823; 0.392) 0.486 0  
Somnolence 2.063 (1.361; 2.764) <0.001 0  
  1. Note:
  2. θ is absolute difference for 24-hour pain intensity.
  3. θ is log-odds ratio for Response, PGI and all tolerability analyses.
  4. τ 2 is between-study heterogeneity.
  5. NNT/NNH: Number needed to treat, number needed to harm. NNTs were calculated for response rate and NNHs were calculated for discontinuation due to adverse events.